BIONTECH SEES POTENTIAL TO SUPPLY 3 BILLION DOSES IN 2022
BioNTech SE could have capacity to make 3 billion doses of Covid-19 vaccine with U.S. partner Pfizer Inc. next year, the German company’s chief executive officer said, making their pioneering shot far more widely available around the world.
“In principle, we could further increase manufacturing capacity,” Ugur Sahin said Tuesday in an interview with Bloomberg TV. “It depends on demand, it depends on factors such as if an additional boost to vaccinations is required.”
Demand is growing around the world for Covid vaccines that countries desperately need to breathe back life into economies, return children to schools and get people back into offices and shops. Both the U.S. and Europe have sought to accelerate vaccine deliveries this year as new, more aggressive variants of the virus spread.
“We have an order book of already 1.3 billion orders, which is already fixed,” Sahin said. “We are discussing additional doses -- hundreds of millions of doses as options -- with government organizations.”
BioNTech shares rose as much as 1.3% early Wednesday in Frankfurt.
The two companies have committed to make 2 billion doses of their two-shot vaccine this year. Pfizer promised to ship two-thirds of the U.S.’s 300 million-dose order by the end of May. In the European Union, the partners have promised to ship at least 500 million doses this year, with an option for an additional 100 million doses.